Flicker, L (2001). Piracetam for dementia or cognitive impairment.. The Cochrane Database of Systematic Reviews (2): CD001011. PMID11405971. DOI: 10.1002/14651858.CD001011.
(september 2017). Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs31 (9): 759–776. PMID28786085. DOI: 10.1007/s40263-017-0459-3. “Other medications have been considered or tried for the treatment of VCI or VaD. These include [...] piracetam. There is no convincing evidence about the efficacy of these medications in the treatment of VCI.”.
(februari 2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs70 (3): 287–312. PMID20166767. DOI: 10.2165/11319230-000000000-00000.
(juli 2016). Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs30 (7): 575–87. PMID27236454. DOI: 10.1007/s40263-016-0348-1.
(oktober 2017). Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation37 (10): 901–928. PMID28756557. DOI: 10.1007/s40261-017-0558-4.
(1983). Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology81 (2): 100–106. PMID6415738. DOI: 10.1007/BF00429000.
(1978). Piracetam in the treatment of post-concussional syndrome. A double-blind study. European Neurology17 (1): 50–55. PMID342247. DOI: 10.1159/000114922.
(maart 2010). Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. Journal of Medicinal Chemistry53 (5): 2197–203. PMID20163115. PMC2872987. DOI: 10.1021/jm901905j.
Giurgea, Corneliu E. (januari 1982). The nootropic concept and its prospective implications. Drug Development Research2 (5): 441–446. ISSN: 1098-2299. DOI: 10.1002/ddr.430020505.
(1987). Effect of Piracetam on electrocorticogram and local cerebral glucose utilization in the rat. General Pharmacology18 (2): 205–11. PMID3569848. DOI: 10.1016/0306-3623(87)90252-7.
(oktober 1976). Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine. Biochemical Pharmacology25 (20): 2241–4. PMID985556. DOI: 10.1016/0006-2952(76)90004-6.
(juli 2006). Rapid determination of piracetam in human plasma and cerebrospinal fluid by micellar electrokinetic chromatography with sample direct injection. J Chromatogr A1120 (1-2): 27–34. PMID16343512. DOI: 10.1016/j.chroma.2005.11.071.
(oktober 2012). A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons. Exp Biol Med (Maywood)237 (10): 1209–18. PMID23045722. DOI: 10.1258/ebm.2012.012128.
Flicker, L (2001). Piracetam for dementia or cognitive impairment.. The Cochrane Database of Systematic Reviews (2): CD001011. PMID11405971. DOI: 10.1002/14651858.CD001011.
(september 2017). Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs31 (9): 759–776. PMID28786085. DOI: 10.1007/s40263-017-0459-3. “Other medications have been considered or tried for the treatment of VCI or VaD. These include [...] piracetam. There is no convincing evidence about the efficacy of these medications in the treatment of VCI.”.
(februari 2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs70 (3): 287–312. PMID20166767. DOI: 10.2165/11319230-000000000-00000.
(juli 2016). Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs30 (7): 575–87. PMID27236454. DOI: 10.1007/s40263-016-0348-1.
(oktober 2017). Effects of Central Nervous System Drugs on Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation37 (10): 901–928. PMID28756557. DOI: 10.1007/s40261-017-0558-4.
(1983). Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology81 (2): 100–106. PMID6415738. DOI: 10.1007/BF00429000.
(1978). Piracetam in the treatment of post-concussional syndrome. A double-blind study. European Neurology17 (1): 50–55. PMID342247. DOI: 10.1159/000114922.
(maart 2010). Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. Journal of Medicinal Chemistry53 (5): 2197–203. PMID20163115. PMC2872987. DOI: 10.1021/jm901905j.
(2005). Piracetam--an old drug with novel properties?. Acta Poloniae Pharmaceutica62 (5): 405–9. PMID16459490.
(1987). Effect of Piracetam on electrocorticogram and local cerebral glucose utilization in the rat. General Pharmacology18 (2): 205–11. PMID3569848. DOI: 10.1016/0306-3623(87)90252-7.
(oktober 1976). Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine. Biochemical Pharmacology25 (20): 2241–4. PMID985556. DOI: 10.1016/0006-2952(76)90004-6.
(1986). Piracetam: physiological disposition and mechanism of action. Advances in Neurology43: 675–85. PMID3946121.
(juli 2006). Rapid determination of piracetam in human plasma and cerebrospinal fluid by micellar electrokinetic chromatography with sample direct injection. J Chromatogr A1120 (1-2): 27–34. PMID16343512. DOI: 10.1016/j.chroma.2005.11.071.
(oktober 2012). A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons. Exp Biol Med (Maywood)237 (10): 1209–18. PMID23045722. DOI: 10.1258/ebm.2012.012128.
Giurgea, Corneliu E. (januari 1982). The nootropic concept and its prospective implications. Drug Development Research2 (5): 441–446. ISSN: 1098-2299. DOI: 10.1002/ddr.430020505.
